At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH4524184 in HIV-1 Infected Treatment Naïve Adults
In Brief
A Phase 2 clinical trial evaluating VH4524184, Matching Placebo, and 1 other intervention for HIV Infections. Completed, enrolled 22 participants across 17 sites in 5 countries.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, ability of VH4524184 when given alone to reduce the amount of HIV (viral load) in people with HIV-1 infection who have never received antiretroviral therapy (treatment-naïve). Data from this study will be used to decide how VH4524184 can be best included in a full-treatment regimen for HIV-1 in the future.
Study Details
Timeline
Interventions
VH4524184 was administered as tablets orally at Day 1.
VH4524184 Matching Placebo was administered as tablets orally at Day 1.
Antiretroviral therapy was administered as available and as per investigator's recommendation.